Cord blood cells engineered to fight lung cancer enter human testing
NCT ID NCT05334329
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 35 times
Summary
This early-phase trial tests a new treatment for people with advanced non-small cell lung cancer that has stopped responding to standard immunotherapy. The treatment uses immune cells from umbilical cord blood that are genetically modified to better recognize and attack cancer cells. Some participants also receive an additional immunotherapy drug called atezolizumab. The main goal is to check safety and find the best dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chao Family Comprehensive Cancer Center University of California, Irvine
Orange, California, 92868, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
umbilical cord blood natural killer cells (COH06) with or without atezolizumab
What this could lead to
If this works, it could point toward a new treatment option for advanced lung cancer patients whose cancer no longer responds to standard immunotherapy.
What could go wrong
This is a very early, small Phase 1 trial with only 6 participants, focused mainly on safety and dosing. The approach may not shrink tumors or work for everyone, and there are risks of side effects like cytokine release syndrome.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.